{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:37:04Z","timestamp":1793475424759,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.annonc.2021.08.1748","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T08:02:47Z","timestamp":1629273767000},"page":"1381-1390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance"],"prefix":"10.1016","volume":"32","author":[{"given":"Y.","family":"Loriot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Gu\u00e9gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.X.","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Khettab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Friboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Le Loarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bessede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2021.08.1748_bib1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1748_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.1748_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2021.08.1748_bib4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.08.1748_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-020-00130-7","article-title":"Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy","volume":"4","author":"Recondo","year":"2020","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1748_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.08.1748_bib7","article-title":"Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients","author":"Filbin","year":"2020","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1748_bib8","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2021.08.1748_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predicts immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1748_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jclinpath-2019-205732","article-title":"PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory","volume":"72","author":"Vigliar","year":"2019","journal-title":"J\u00a0Clin Pathol"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1748_bib11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.1748_bib12","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkz114","article-title":"The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads","volume":"47","author":"Liao","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"24","key":"10.1016\/j.annonc.2021.08.1748_bib13","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","article-title":"Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods","volume":"79","author":"Jim\u00e9nez-S\u00e1nchez","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1748_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1748_bib15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1748_bib16","doi-asserted-by":"crossref","first-page":"e000678","DOI":"10.1136\/jitc-2020-000678","article-title":"Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1748_bib17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1748_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1748_bib19","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/s41467-021-22767-z","article-title":"Next generation plasma proteome profiling to monitor health and disease","volume":"12","author":"Zhong","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2021.08.1748_bib20","doi-asserted-by":"crossref","first-page":"107754","DOI":"10.1016\/j.pharmthera.2020.107754","article-title":"The emerging role of leukemia inhibitory factor in cancer and therapy","volume":"221","author":"Zhang","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.1748_bib21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4161\/cc.8.9.8348","article-title":"Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6","volume":"8","author":"Gao","year":"2009","journal-title":"Cell Cycle"},{"issue":"13","key":"10.1016\/j.annonc.2021.08.1748_bib22","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","article-title":"Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells","volume":"110","author":"Duluc","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1748_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1189\/jlb.3MA1016-451RR","article-title":"TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs","volume":"102","author":"Won","year":"2017","journal-title":"J\u00a0Leukoc Biol"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1748_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/08923973.2019.1619761","article-title":"Leukemia inhibitory factor (LIF) modulates the development of dendritic cells in a dual manner","volume":"41","author":"Yaftiyan","year":"2019","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1748_bib25","first-page":"11465","article-title":"Immunization against leukemia inhibitory factor and its receptor suppresses tumor formation of breast cancer initiating cells in BALB\/c mouse","volume":"10","author":"Ghanei","year":"2020","journal-title":"Sci\u00a0Rep"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1748_bib26","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","article-title":"LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy","volume":"10","author":"Pascual-Garc\u00eda","year":"2019","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1748_bib27","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00262-011-1071-x","article-title":"Prognostic impact of B-cell density in cutaneous melanoma","volume":"60","author":"Lad\u00e1nyi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2021.08.1748_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/srep00765","article-title":"12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1748_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1748_bib30","first-page":"7610","article-title":"Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas","volume":"7","author":"Behr","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.1748_bib31","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","article-title":"Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers","volume":"20","author":"Di Caro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.08.1748_bib32","doi-asserted-by":"crossref","unstructured":"Schram A, Borazanci E, Brana I, et\u00a0al. Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 suppl):Abstract nr CT147.","DOI":"10.1158\/1538-7445.AM2020-CT147"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421039788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421039788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:45Z","timestamp":1760335665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421039788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0923753421039788"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1748","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}